Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
The APPLAUDS trial will evaluate mivelsiran, an intrathecally delivered siRNA targeting amyloid precursor protein, in cognitively stable adults aged 40 to 55 with early-stage Down syndrome and early-stage Alzheimer disease who have elevated amyloid burden.
Leslie M. Thompson, PhD; Ravi Rajmohan, MD, and Jefferson W. Chen, MD, from UCI Health discuss the rationale, delivery, and early steps of REGEN4HD, the world's first neural stem cell phase 1b/2a clinical trial for Huntington disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics
The director of the Division of Neuroscience at IRCCS Istituto Ortopedico Rizzoli discusses why targeting shared biologic pathways, rather than individual mutations, may represent a promising therapeutic strategy for Charcot-Marie-Tooth disease. [WATCH TIME: 2 minutes]
An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, whereas past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]
The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.
Fariha Abbasi-Feinberg, MD, FAASM, FAAN, newly installed president of the American Academy of Sleep Medicine and medical director of sleep medicine at Millennium Physician Group, shares her clinical and policy priorities for the year ahead and her vision for the future of sleep medicine.
The professor of neurology and neuroscience at Johns Hopkins University School of Medicine discussed the ongoing debate around animal models in neuropathy research, the rise of iPSC-derived systems, and why he believes both approaches are needed going forward.
Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.
Matthew Evans, BM, BCh, DPhil, a consultant neurologist at the University of Oxford, discusses the diagnostic approach to small fiber neuropathy and the challenges of confirming immune-mediated disease. [WATCH TIME: 3 minutes]
A 10-protein serum signature identified through longitudinal proteomics significantly stratified relapse risk in NMOSD patients, with the 2 strongest markers showing an association with relapse more than 8 months out on average.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is retinal biomarkers for central nervous system disease!
The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.
Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.
Twelve-month phase 1/2 data show SKY-0515-treated patients trending favorably versus natural history expectations across motor, functional, and cognitive endpoints, while 65% of patients and 50% of clinicians reported disease improvement.
Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.
A nonrandomized controlled trial found that an MCT program added to standard rehabilitation significantly improved MoCA scores and reduced anxiety and depression at 4 and 12 weeks compared with standard care alone.
Johnson, who set the single-season NFL rushing record in 2009, went public with his diagnosis on Good Morning America, saying he hopes his story accelerates research and awareness of the disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sex-based differences in neurology!
Doris D. Wang, MD, PhD, an associate professor of neurological surgery at UCSF, discusses a newly published adaptive deep brain stimulation system that adjusts in real time during walking and what it means for the future of Parkinson disease care.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]
REGENXBIO expects to resubmit the BLA for clemidsogene lanparvovec in Q3 2026 after the FDA confirmed existing CAMPSIITE data are sufficient for accelerated approval consideration.
The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.
Ashish Raj, PhD, professor of radiology and biomedical imaging at UCSF, discusses a newly developed AI model that predicts current and future cognitive impairment from a single baseline MRI scan in patients across the Alzheimer disease spectrum.
The professor of neuroscience at the University of Cambridge discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.
Three of 6 patients in the first low-dose cohort achieved seizure reductions of 79% to 100% at months 4 through 6, with no serious adverse events reported to date.
Patients with incident TD incurred annual all-cause healthcare costs nearly double those of matched non-TD controls, driven primarily by inpatient encounters, while fewer than a quarter received any approved treatment.
Matthew Evans, BM, BCh, DPhil, consultant neurologist at Imperial College Healthcare NHS Trust, discusses emerging evidence for immune-mediated small fiber neuropathy, current diagnostic challenges, and the need for better clinical trials and biomarkers.
Phase 3 data showed a 53% reduction in relapse risk versus placebo, and ecopipam could become the first non-antipsychotic option ever approved for Tourette syndrome.
